Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

被引：145

作者：

Doherty, L.

Gigas, D. C.

Kesari, S.

Drappatz, J.

Kim, R.

Zimmerman, J.

Ostrowsky, L.

Wen, P. Y.

机构：

[1] Brigham & Womens Hosp, Ctr Neurooncol, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, Div Canc Neurol, Boston, MA 02115 USA

[3] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA

来源：

NEUROLOGY | 2006年 / 67卷 / 01期

关键词：

D O I：

10.1212/01.wnl.0000223844.77636.29

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor ( EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR ( mammalian target of rapamycin) inhibitor sirolimus. The regimens were reasonably well tolerated. Nineteen percent of patients experienced a partial response and 50% had stable disease. Six-month progression-free survival for glioblastoma patients was 25%.

引用

页码：156 / 158

页数：3

共 10 条

[1] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme [J].

Chang, SM ;

Wen, P ;

Cloughesy, T ;

Greenberg, H ;

Schiff, D ;

Conrad, C ;

Fink, K ;

Robins, HI ;

De Angelis, L ;

Raizer, J ;

Hess, K ;

Aldape, K ;

Lamborn, KR ;

Kuhn, J ;

Dancey, J ;

Prados, MD .

INVESTIGATIONAL NEW DRUGS, 2005, 23 (04) :357-361

[2] Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study [J].

Galanis, E ;

Buckner, JC ;

Maurer, MJ ;

Kreisberg, JL ;

Ballman, K ;

Boni, J ;

Peralba, JM ;

Jenkins, RB ;

Dakhil, SR ;

Morton, RF ;

Jaeckle, KA ;

Scheithauer, BW ;

Dancey, J ;

Hidalgo, M ;

Walsh, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5294-5304

[3]

Goudar RK, 2005, MOL CANCER THER, V4, P101

[4] Targeted molecular therapy of malignant gliomas [J].

Kesari S. ;

Ramakrishna N. ;

Sauvageot C. ;

Stiles C.D. ;

Wen P.Y. .

Current Neurology and Neuroscience Reports, 2005, 5 (3) :186-197

[5]

Levin Victor A., 1997, P2022

[6] RESPONSE CRITERIA FOR PHASE-II STUDIES OF SUPRATENTORIAL MALIGNANT GLIOMA [J].

MACDONALD, DR ;

CASCINO, TL ;

SCHOLD, SC ;

CAIRNCROSS, JG .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1277-1280

[7] Malignant glioma: genetics and biology of a grave matter [J].

Maher, EA ;

Furnari, FB ;

Bachoo, RM ;

Rowitch, DH ;

Louis, DM ;

Cavenee, WK ;

DePinho, RA .

GENES & DEVELOPMENT, 2001, 15 (11) :1311-1333

[8] Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors [J].

Mellinghoff, IK ;

Wang, MY ;

Vivanco, I ;

Haas-Kogan, DA ;

Zhu, SJ ;

Dia, EQ ;

Lu, KV ;

Yoshimoto, K ;

Huang, JHY ;

Chute, DJ ;

Riggs, BL ;

Horvath, S ;

Liau, LM ;

Cavenee, WK ;

Rao, PN ;

Beroukhim, R ;

Peck, TC ;

Lee, JC ;

Sellers, WR ;

Stokoe, D ;

Prados, M ;

Cloughesy, TF ;

Sawyers, CL ;

Mischel, PS .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (19) :2012-2024

[9] HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme [J].

Raizer, RJ .

JOURNAL OF NEURO-ONCOLOGY, 2005, 74 (01) :77-86

[10] Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials [J].

Wong, ET ;

Hess, KR ;

Gleason, MJ ;

Jaeckle, KA ;

Kyritsis, AP ;

Prados, MD ;

Levin, VA ;

Yung, WKA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2572-2578

← 1 →